Research

Clinical research is critical to the advancement of perinatal mental health treatment. Our program has several ongoing clinical research studies aimed at improving treatments for perinatal mood, pain, and opioid use. Below are brief descriptions of ongoing studies and opportunities to participate in clinical research.

Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): A Pragmatic Randomized Trial Comparing Extended-Release and Daily Buprenorphine Formulations

The purpose of this research study is to evaluate the impact of treating Opioid Use Disorder in pregnant women with extended-release buprenorphine, compared to sublingual buprenorphine, on mother and infant outcomes. The study consists of a screening phase, weekly medication visits, and research visits throughout pregnancy and until 12 months postpartum.You may be eligible to join if:

  • You are 18-41 years old
  • You are currently pregnant
  • You have opioid use disorder

For more information and to see if you qualify please contact Edie Douglas at 843-792-0403 or douglaed@musc.edu 

Web Based Treatment for Perinatal Opioid Use Disorder

This purpose of this research study is to collect feedback from participants about a web-based program for opioid misuse and opioid use disorder. Participants will be asked to review web-based content and take part in focus groups (group discussions) and individual interviews to provide feedback on the content. The study team is looking for pregnant women or women who have been pregnant in the past 2 years who misuse opioids or have opioid use disorder, as well as obstetric providers who treat pregnant women with opioid misuse and opioid use disorder to participate. 

You may be eligible to join if you:

  • Are currently pregnant or have been pregnant in the past two years and misuse opioids or have opioid use disorder
  • Have current board certification in obstetrics and gynecology, or a degree in midwifery or advanced practice nursing; or are an OBGYN resident, MFM fellow or medical student

For more information and to see if you qualify please contact Edie Douglas at 843-792-0403 or douglaed@musc.edu

Evaluation of the Women’s Reproductive Behavioral Telehealth Program

The purpose of this research study is to examine barriers and facilitators to successful adoption and implementation of the MUSC Women’s Reproductive Behavioral Telehealth (WRBT) Program. Staff and providers at sites who participate in the MUSC Women's Reproductive Behavioral Telehealth (WRBT) Program will be asked to participate in individual interviews or focus groups (group discussions) about their experience with the telemedicine program and fill out surveys. Patients in the WRBT Program will be asked to fill out surveys about their telemedicine experience. 

You may be eligible to join if you:

  • Are a staff or provider at a WRBT telemedicine site in South Carolina
  • Are a patient who participates in the WRBT program

For more information and to see if you qualify please contact Edie Douglas at 843-792-0403 or douglaed@musc.edu

Postpartum Depression ACT

PPD ACT is a research app for women who have ever experienced postpartum depression (PPD) or psychosis (PPP). The goal of the study is to improve detection, treatment and prevention of PPD and PPP by finding the genetic basis of these disorders. Women who participate will download the PPD ACT app, fill out questionnaires and if eligible, submit a saliva sample.

You may be eligible to join if you:

  • Are female aged 18 or above
  • Have had a live birth
  • Have an iOS or Android device

For more information, find us on the web at PPD ACT, Twitterpact.questions@med.unc.edu or find the app in the iTunes or Google Play store by searching “PPD ACT.”

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, & Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects with Severe Postpartum Depression & Adult Female Subjects with Moderate Postpartum Depression*

This is a research study evaluating an investigational medication (SAGE-547, allopregnanolone) in women with moderate to severe postpartum depression. The specific purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of SAGE-547 as a treatment for women with severe or moderate postpartum depression (PPD), an area of high unmet medical need. The study consists of an up to 7-day Screening Period, 3-day inpatient Treatment Period, and 30-day Follow-up Period. Assessments and laboratory samples are collected during the Treatment Period and the Follow-up Period.

*We are no longer enrolling participants in this study. This medication has been approved by the FDA for Postpartum Depression and is being offered as a treatment option in our clinic.